Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
40 hedge funds and large institutions have $64.8M invested in Cellular Biomedicine Group, Inc. in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 3 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
9% more capital invested
Capital invested by funds: $59.4M → $64.8M (+$5.34M)
0% more funds holding
Funds holding: 40 → 40 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$2.38M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$2.35M |
| 3 |
BlackRock
New York
|
+$1.69M |
| 4 |
AIC
AWM Investment Company
New York
|
+$1.31M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$865K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$604K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$176K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$84.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$56.5K |
CBMG Hedge Fund Activity: Q2 2019 in Review
40 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q2 2019, worth a combined $64.8M — up 9% from $59.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CBMG positions and 3 closed out — a net gain of 2 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $2.38M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $865K sold.
- 40 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $64.8M of Cellular Biomedicine Group, Inc. stock for Q2 2019, up 9% quarter-over-quarter.
- 5 funds opened new Cellular Biomedicine Group, Inc. positions in Q2 2019 and 3 closed out, a net change of +2 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q2 2019 was Sumitomo Mitsui Trust Group, an estimated $2.38M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q2 2019 was Alyeska Investment Group, an estimated $865K sold.
Based on aggregated 13F filings for Q2 2019.